Effects of Moxonidine and Low-Calorie Diet: Cardiometabolic Benefits from Combination of Both Therapies

Elisabeth A. Lambert, Carolina I. Sari, Nina Eikelis, Sarah E. Phillips, Mariee Grima, Nora E. Straznicky, John B. Dixon, Murray Esler, Markus P. Schlaich, Geoffrey A. Head, Gavin W. Lambert

    Research output: Contribution to journalArticle

    6 Citations (Scopus)

    Abstract

    Objective: Because sympathetic nervous system activity plays a detrimental role in metabolic and cardiovascular health, this study compared the effects of a centrally acting sympatholytic agent, the effects of a weight loss (WL) program using a low-calorie diet, and the effects of a combination of both. Methods: Young (18-30 years) male subjects with overweight (BMI > 25 kg/m2) were allocated to a WL program (n = 10), a moxonidine treatment course (M; n = 10, 0.4 mg/d), a combination of both (WL + M; n = 11), or to a control (C) group (n = 6) for 6 months. Muscle sympathetic nerve activity (MSNA), endothelial function, renal function (Cockcroft-Gault formula), and the metabolic profile were assessed before and after intervention. Results: WL occurred in the WL and WL + M groups (−7.6 ± 1.9 kg, P < 0.001 in both). MSNA and systolic blood pressure decreased similarly in the WL, M, and WL + M groups (by ∼10 bursts/min, P < 0.001, and by ∼9 mm Hg, P < 0.05). All other parameters for the WL, C, and M groups remained unchanged. In the WL + M group, decreased total cholesterol (−0.78 ± 0.23 mmol/L, P < 0.001), decreased low-density lipoprotein cholesterol (−0.49 ± 0.16 mmol/L, P < 0.01), decreased insulin (−6.5 ± 2.8 mmol/L, P < 0.05), and attenuated glomerular hyperfiltration (−19 ± 5 mL/min, P < 0.01) occurred. Conclusions: The combination of moxonidine with a WL program has beneficial effects on aspects of the metabolic profile and end organ damage in young males with overweight.

    Original languageEnglish
    Pages (from-to)1894-1902
    Number of pages9
    JournalObesity
    Volume25
    Issue number11
    DOIs
    Publication statusPublished - 1 Nov 2017

    Fingerprint

    moxonidine
    Caloric Restriction
    Weight Loss
    Weight Reduction Programs
    Sympatholytics
    Metabolome
    Therapeutics
    Blood Pressure
    Muscles
    Sympathetic Nervous System

    Cite this

    Lambert, E. A., Sari, C. I., Eikelis, N., Phillips, S. E., Grima, M., Straznicky, N. E., ... Lambert, G. W. (2017). Effects of Moxonidine and Low-Calorie Diet: Cardiometabolic Benefits from Combination of Both Therapies. Obesity, 25(11), 1894-1902. https://doi.org/10.1002/oby.21962
    Lambert, Elisabeth A. ; Sari, Carolina I. ; Eikelis, Nina ; Phillips, Sarah E. ; Grima, Mariee ; Straznicky, Nora E. ; Dixon, John B. ; Esler, Murray ; Schlaich, Markus P. ; Head, Geoffrey A. ; Lambert, Gavin W. / Effects of Moxonidine and Low-Calorie Diet : Cardiometabolic Benefits from Combination of Both Therapies. In: Obesity. 2017 ; Vol. 25, No. 11. pp. 1894-1902.
    @article{016d85642ce84f3bb32d130053dd5827,
    title = "Effects of Moxonidine and Low-Calorie Diet: Cardiometabolic Benefits from Combination of Both Therapies",
    abstract = "Objective: Because sympathetic nervous system activity plays a detrimental role in metabolic and cardiovascular health, this study compared the effects of a centrally acting sympatholytic agent, the effects of a weight loss (WL) program using a low-calorie diet, and the effects of a combination of both. Methods: Young (18-30 years) male subjects with overweight (BMI > 25 kg/m2) were allocated to a WL program (n = 10), a moxonidine treatment course (M; n = 10, 0.4 mg/d), a combination of both (WL + M; n = 11), or to a control (C) group (n = 6) for 6 months. Muscle sympathetic nerve activity (MSNA), endothelial function, renal function (Cockcroft-Gault formula), and the metabolic profile were assessed before and after intervention. Results: WL occurred in the WL and WL + M groups (−7.6 ± 1.9 kg, P < 0.001 in both). MSNA and systolic blood pressure decreased similarly in the WL, M, and WL + M groups (by ∼10 bursts/min, P < 0.001, and by ∼9 mm Hg, P < 0.05). All other parameters for the WL, C, and M groups remained unchanged. In the WL + M group, decreased total cholesterol (−0.78 ± 0.23 mmol/L, P < 0.001), decreased low-density lipoprotein cholesterol (−0.49 ± 0.16 mmol/L, P < 0.01), decreased insulin (−6.5 ± 2.8 mmol/L, P < 0.05), and attenuated glomerular hyperfiltration (−19 ± 5 mL/min, P < 0.01) occurred. Conclusions: The combination of moxonidine with a WL program has beneficial effects on aspects of the metabolic profile and end organ damage in young males with overweight.",
    author = "Lambert, {Elisabeth A.} and Sari, {Carolina I.} and Nina Eikelis and Phillips, {Sarah E.} and Mariee Grima and Straznicky, {Nora E.} and Dixon, {John B.} and Murray Esler and Schlaich, {Markus P.} and Head, {Geoffrey A.} and Lambert, {Gavin W.}",
    year = "2017",
    month = "11",
    day = "1",
    doi = "10.1002/oby.21962",
    language = "English",
    volume = "25",
    pages = "1894--1902",
    journal = "Obesity Research",
    issn = "1071-7323",
    publisher = "Wiley-Blackwell",
    number = "11",

    }

    Lambert, EA, Sari, CI, Eikelis, N, Phillips, SE, Grima, M, Straznicky, NE, Dixon, JB, Esler, M, Schlaich, MP, Head, GA & Lambert, GW 2017, 'Effects of Moxonidine and Low-Calorie Diet: Cardiometabolic Benefits from Combination of Both Therapies' Obesity, vol. 25, no. 11, pp. 1894-1902. https://doi.org/10.1002/oby.21962

    Effects of Moxonidine and Low-Calorie Diet : Cardiometabolic Benefits from Combination of Both Therapies. / Lambert, Elisabeth A.; Sari, Carolina I.; Eikelis, Nina; Phillips, Sarah E.; Grima, Mariee; Straznicky, Nora E.; Dixon, John B.; Esler, Murray; Schlaich, Markus P.; Head, Geoffrey A.; Lambert, Gavin W.

    In: Obesity, Vol. 25, No. 11, 01.11.2017, p. 1894-1902.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Effects of Moxonidine and Low-Calorie Diet

    T2 - Cardiometabolic Benefits from Combination of Both Therapies

    AU - Lambert, Elisabeth A.

    AU - Sari, Carolina I.

    AU - Eikelis, Nina

    AU - Phillips, Sarah E.

    AU - Grima, Mariee

    AU - Straznicky, Nora E.

    AU - Dixon, John B.

    AU - Esler, Murray

    AU - Schlaich, Markus P.

    AU - Head, Geoffrey A.

    AU - Lambert, Gavin W.

    PY - 2017/11/1

    Y1 - 2017/11/1

    N2 - Objective: Because sympathetic nervous system activity plays a detrimental role in metabolic and cardiovascular health, this study compared the effects of a centrally acting sympatholytic agent, the effects of a weight loss (WL) program using a low-calorie diet, and the effects of a combination of both. Methods: Young (18-30 years) male subjects with overweight (BMI > 25 kg/m2) were allocated to a WL program (n = 10), a moxonidine treatment course (M; n = 10, 0.4 mg/d), a combination of both (WL + M; n = 11), or to a control (C) group (n = 6) for 6 months. Muscle sympathetic nerve activity (MSNA), endothelial function, renal function (Cockcroft-Gault formula), and the metabolic profile were assessed before and after intervention. Results: WL occurred in the WL and WL + M groups (−7.6 ± 1.9 kg, P < 0.001 in both). MSNA and systolic blood pressure decreased similarly in the WL, M, and WL + M groups (by ∼10 bursts/min, P < 0.001, and by ∼9 mm Hg, P < 0.05). All other parameters for the WL, C, and M groups remained unchanged. In the WL + M group, decreased total cholesterol (−0.78 ± 0.23 mmol/L, P < 0.001), decreased low-density lipoprotein cholesterol (−0.49 ± 0.16 mmol/L, P < 0.01), decreased insulin (−6.5 ± 2.8 mmol/L, P < 0.05), and attenuated glomerular hyperfiltration (−19 ± 5 mL/min, P < 0.01) occurred. Conclusions: The combination of moxonidine with a WL program has beneficial effects on aspects of the metabolic profile and end organ damage in young males with overweight.

    AB - Objective: Because sympathetic nervous system activity plays a detrimental role in metabolic and cardiovascular health, this study compared the effects of a centrally acting sympatholytic agent, the effects of a weight loss (WL) program using a low-calorie diet, and the effects of a combination of both. Methods: Young (18-30 years) male subjects with overweight (BMI > 25 kg/m2) were allocated to a WL program (n = 10), a moxonidine treatment course (M; n = 10, 0.4 mg/d), a combination of both (WL + M; n = 11), or to a control (C) group (n = 6) for 6 months. Muscle sympathetic nerve activity (MSNA), endothelial function, renal function (Cockcroft-Gault formula), and the metabolic profile were assessed before and after intervention. Results: WL occurred in the WL and WL + M groups (−7.6 ± 1.9 kg, P < 0.001 in both). MSNA and systolic blood pressure decreased similarly in the WL, M, and WL + M groups (by ∼10 bursts/min, P < 0.001, and by ∼9 mm Hg, P < 0.05). All other parameters for the WL, C, and M groups remained unchanged. In the WL + M group, decreased total cholesterol (−0.78 ± 0.23 mmol/L, P < 0.001), decreased low-density lipoprotein cholesterol (−0.49 ± 0.16 mmol/L, P < 0.01), decreased insulin (−6.5 ± 2.8 mmol/L, P < 0.05), and attenuated glomerular hyperfiltration (−19 ± 5 mL/min, P < 0.01) occurred. Conclusions: The combination of moxonidine with a WL program has beneficial effects on aspects of the metabolic profile and end organ damage in young males with overweight.

    UR - http://www.scopus.com/inward/record.url?scp=85028589210&partnerID=8YFLogxK

    U2 - 10.1002/oby.21962

    DO - 10.1002/oby.21962

    M3 - Article

    VL - 25

    SP - 1894

    EP - 1902

    JO - Obesity Research

    JF - Obesity Research

    SN - 1071-7323

    IS - 11

    ER -

    Lambert EA, Sari CI, Eikelis N, Phillips SE, Grima M, Straznicky NE et al. Effects of Moxonidine and Low-Calorie Diet: Cardiometabolic Benefits from Combination of Both Therapies. Obesity. 2017 Nov 1;25(11):1894-1902. https://doi.org/10.1002/oby.21962